American multinational healthcare company and retailer
Health-tech data sharing is advancing, with real-time interoperability and AI-assisted tools promised by CVS Health and partners. Meanwhile, lawsuits involving Epic and Health Gorilla highlight ongoing security gaps as regulators push for seamless sharing. Biometric risks from AI-fuelled fingerprint extraction add new concerns for consumer protection.
The 340B program, which lets hospitals buy discounted outpatient drugs for low-income patients, is facing a new CMS rule changing reimbursement formulas to reduce payments by about 40%. The move aims to lower patient costs but could shrink hospital revenues and affect services and jobs. The rule follows an executive order in 2025 and reflects ongoing political battles between hospitals and the pharmaceutical industry.
CNBC’s 2026 America’s Top States for Business quality-of-life rankings have drawn criticism from conservatives who say the methodology unfairly targets red states. Critics argue the list conflicts with population growth data and different state policy outcomes.
The White House has convened a meeting with AI leaders to review a proposed cybersecurity framework for advanced models, following OpenAI's recent agent hacks and calls for greater government access. Attendees include executives from Hugging Face, Anthropic, and others; Meta and Alphabet may participate. Markets show mixed responses as investors watch the policy discussion unfold.
Foundayo, the oral GLP-1 weight-loss pill by Eli Lilly, has been authorised by the MHRA for weight management and type 2 diabetes. It will be available privately; NHS adoption depends on NICE evaluation. Several UK outlets report on uptake, pricing, side effects and competing pills, including Wegovy and Wegovy HD.
CVS Health has raised its 2026 guidance, citing stronger profits from its insurance and retail pharmacy segments and a marked improvement in its Aetna unit. The company is expanding GLP-1 weight-loss access through MinuteClinic, while flagging higher medical costs and macro risks.